BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24781018)

  • 1. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.
    López-Guerra M; Xargay-Torrent S; Rosich L; Montraveta A; Roldán J; Matas-Céspedes A; Villamor N; Aymerich M; López-Otín C; Pérez-Galán P; Roué G; Campo E; Colomer D
    Leukemia; 2015 Jan; 29(1):96-106. PubMed ID: 24781018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells.
    López-Guerra M; Xargay-Torrent S; Fuentes P; Roldán J; González-Farré B; Rosich L; Silkenstedt E; García-León MJ; Lee-Vergés E; Giménez N; Giró A; Aymerich M; Villamor N; Delgado J; López-Guillermo A; Puente XS; Campo E; Toribio ML; Colomer D
    Oncogene; 2020 Feb; 39(6):1185-1197. PubMed ID: 31616059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive activation of NF-κB signaling by NOTCH1 mutations in chronic lymphocytic leukemia.
    Xu ZS; Zhang JS; Zhang JY; Wu SQ; Xiong DL; Chen HJ; Chen ZZ; Zhan R
    Oncol Rep; 2015 Apr; 33(4):1609-14. PubMed ID: 25633905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
    Secchiero P; Melloni E; di Iasio MG; Tiribelli M; Rimondi E; Corallini F; Gattei V; Zauli G
    Blood; 2009 Apr; 113(18):4300-8. PubMed ID: 19190243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
    Samon JB; Castillo-Martin M; Hadler M; Ambesi-Impiobato A; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Jakubczak J; Randolph S; Cordon-Cardo C; Ferrando AA
    Mol Cancer Ther; 2012 Jul; 11(7):1565-75. PubMed ID: 22504949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation.
    Rosati E; Sabatini R; De Falco F; Del Papa B; Falzetti F; Di Ianni M; Cavalli L; Fettucciari K; Bartoli A; Screpanti I; Marconi P
    Int J Cancer; 2013 Apr; 132(8):1940-53. PubMed ID: 23001755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
    Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
    Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
    Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
    Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
    Bo MD; Del Principe MI; Pozzo F; Ragusa D; Bulian P; Rossi D; Capelli G; Rossi FM; Niscola P; Buccisano F; Bomben R; Zucchetto A; Maurillo L; de Fabritiis P; Amadori S; Gaidano G; Gattei V; Del Poeta G
    Ann Hematol; 2014 Oct; 93(10):1765-74. PubMed ID: 24923451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.
    Pozzo F; Bittolo T; Vendramini E; Bomben R; Bulian P; Rossi FM; Zucchetto A; Tissino E; Degan M; D'Arena G; Di Raimondo F; Zaja F; Pozzato G; Rossi D; Gaidano G; Del Poeta G; Gattei V; Dal Bo M
    Leukemia; 2017 Nov; 31(11):2407-2415. PubMed ID: 28321119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
    Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
    Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells.
    Han B; Liu SH; Guo WD; Zhang B; Wang JP; Cao YK; Liu J
    World J Gastroenterol; 2015 Sep; 21(33):9727-35. PubMed ID: 26361419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
    Zhang CC; Pavlicek A; Zhang Q; Lira ME; Painter CL; Yan Z; Zheng X; Lee NV; Ozeck M; Qiu M; Zong Q; Lappin PB; Wong A; Rejto PA; Smeal T; Christensen JG
    Clin Cancer Res; 2012 Sep; 18(18):5008-19. PubMed ID: 22806875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1-Stat3.
    Wu CX; Xu A; Zhang CC; Olson P; Chen L; Lee TK; Cheung TT; Lo CM; Wang XQ
    Mol Cancer Ther; 2017 Aug; 16(8):1531-1543. PubMed ID: 28522590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NOTCH1 mutations in CLL associated with trisomy 12.
    Balatti V; Bottoni A; Palamarchuk A; Alder H; Rassenti LZ; Kipps TJ; Pekarsky Y; Croce CM
    Blood; 2012 Jan; 119(2):329-31. PubMed ID: 22086416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.
    Benedetti D; Tissino E; Pozzo F; Bittolo T; Caldana C; Perini C; Martorelli D; Bravin V; D'Agaro T; Rossi FM; Bomben R; Santinelli E; Zaja F; Pozzato G; Chiarenza A; Di Raimondo F; Del Poeta G; Rossi D; Gaidano G; Dal Bo M; Gattei V; Zucchetto A
    Leukemia; 2018 Mar; 32(3):654-662. PubMed ID: 28935990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
    Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia.
    Arruga F; Gizdic B; Serra S; Vaisitti T; Ciardullo C; Coscia M; Laurenti L; D'Arena G; Jaksic O; Inghirami G; Rossi D; Gaidano G; Deaglio S
    Leukemia; 2014 May; 28(5):1060-70. PubMed ID: 24170027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.